Lymphoma

>

Latest News

Graphic depicting a seal that reads "FDA Approval"
FDA Approves Tafasitamab Combo for R/R Follicular Lymphoma

June 18th 2025

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory follicular lymphoma.

Graphic of a clipboard that reads "FDA"
Zanubrutinib Tablets Greenlit by FDA for All Approved Indications

June 12th 2025

Graphic of blood cells
Zilovertamab Vedotin Plus R-GemOx Shows Activity in R/R DLBCL

June 7th 2025

Image of red blood cells
Large Clonal Hematopoiesis Clones Linked to Shorter Survival in MCL

May 25th 2025

Anatomical image of a person's lymphatic system
Ibrutinib/Nivolumab Yields Activity in Relapsed CNS Lymphoma

May 16th 2025

More News

Hodgkin Lymphoma Survivors May Be at Greater Risk for Breast Cancer

Hodgkin Lymphoma Survivors May Be at Greater Risk for Breast Cancer

Kristie L. Kahl
March 6th 2018

Radiotherapy treatments for Hodgkin lymphoma may raise the risk of certain breast cancer subtypes, a study of data on women survivors from the Surveillance, Epidemiology, and End Results (SEER) registries revealed.

Treatment Benefits of Brentuximab Vedotin Outweigh Risk of Peripheral Neuropathy

Treatment Benefits of Brentuximab Vedotin Outweigh Risk of Peripheral Neuropathy

Lauren M. Green
January 30th 2017

Despite peripheral neuropathy associated with brentuximab vedotin in patients with lymphoma, patients believe the better outcomes are worth the risk of neuropathy.

Telephone Intervention Reduces Unplanned Hospitalizations for Patients With Blood Cancers

Telephone Intervention Reduces Unplanned Hospitalizations for Patients With Blood Cancers

Lauren M. Green
April 30th 2015

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.

<1
...
34567